MiR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Manfè, Valentina ^a   Biskup, Edyta ^a   Rosbjerg, Anne ^a   Kamstrup, Maria ^a   Skov, Anne Guldhammer ^a   Lerche, Catharina Margrethe ^a   Lauenborg, Britt Thyssing ^a,b   Ødum, Niels ^b,c   Gniadecki, Robert ^a,c  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DOXORUBICIN; GAMMA SECRETASE INHIBITOR; MICRORNA; MICRORNA 122; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN122 MICRORNA, HUMAN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MYCOSIS FUNGOIDES; SEZARY CELL; T LYMPHOCYTE; UPREGULATION; AGED; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855297304     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029541     Document Type: Article

References (51)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768-3785.
2. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, et al. (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98: 993-1001.
3. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, et al. (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18: 2603-2606.
4. Gniadecki R, Lukowsky A, Rossen K, Madsen HO, Thomsen K, et al. (2003) Bone marrow precursor of extranodal T-cell lymphoma. Blood 102: 3797-3799.
5. Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, et al. (2010) Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 16: 3648-3658.
6. Radtke F, Wilson A, Stark G, Bauer M, van MJ, et al. (1999) Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10: 547-558.
7. Radtke F, Fasnacht N, Macdonald HR, (2010) Notch signaling in the immune system. Immunity 32: 14-27.
8. Yin L, Velazquez OC, Liu ZJ, (2010) Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 80: 690-701.
9. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, et al. (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661.
10. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
11. Bolos V, Grego-Bessa J, de la Pompa JL, (2007) Notch signaling in development and cancer. Endocr Rev 28: 339-363.
12. Schroeter EH, Kisslinger JA, Kopan R, (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393: 382-386.
13. Luistro L, He W, Smith M, Packman K, Vilenchik M, et al. (2009) Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69: 7672-7680.
14. Kamstrup MR, Ralfkiaer E, Skovgaard GL, Gniadecki R, (2008) Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 158: 747-753.
15. Kamstrup MR, Gjerdrum LM, Biskup E, Lauenborg BT, Ralfkiaer E, et al. (2010) Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 116: 2504-2512.
16. Nickoloff BJ, Osborne BA, Miele L, (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22: 6598-6608.
17. Carthew RW, Sontheimer EJ, (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655.
18. Zhang B, Pan X, Cobb GP, Anderson TA, (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12.
19. Ambros V, (2004) The functions of animal microRNAs. Nature 431: 350-355.
20. Lee RC, Ambros V, (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science 294: 862-864.
21. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
22. Manfe V, Holst LM, Rosbjerg A, Kamstrup MR, Kaczkowski B, et al. (2010) Changes in oncomiR expression in CTCL cell lines during apoptosis induced by Notch inhibition. Leuk Res 34: e235-e236.
23. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS, (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
24. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, et al. (2009) MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69: 5761-5767.
25. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC, (1981) Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 154: 1403-1418.
26. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, et al. (1987) A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 279: 293-298.
27. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, et al. (1980) Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55: 409-417.
28. Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath PN, et al. (2008) IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 111: 2181-2189.
29. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, et al. (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110: 1713-1722.
30. Holst LM, Kaczkowski B, Gniadecki R, (2010) Reproducible pattern of microRNA in normal human skin. Exp Dermatol 19: e201-e205.
31. Peltier HJ, Latham GJ, (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14: 844-852.
32. Jorgensen S, Baker A, Moller S, Nielsen BS, (2010) Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 52: 375-381.
33. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, et al. (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 126: 1641-1647.
34. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, et al. (2006) Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107: 2354-2363.
35. Dotto GP, (2009) Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer 9: 587-595.
36. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
37. Ri M, Iida S, Ishida T, Ito A, Yano H, et al. (2008) Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci.
38. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, et al. (2005) Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 11: 3102-3108.
39. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, et al. (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 103: 18261-18266.
40. Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, et al. (2007) Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210.
41. Nair P, Somasundaram K, Krishna S, (2003) Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J Virol 77: 7106-7112.
42. Marrogi AJ, Khan MA, Vonderheid EC, Wood GS, McBurney E, (1999) p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases. J Cutan Pathol 26: 369-378.
43. Li G, Chooback L, Wolfe JT, Rook AH, Felix CA, et al. (1998) Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol 110: 767-770.
44. Baek WK, Kim D, Jung N, Yi YW, Kim JM, et al. (2003) Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. Am J Obstet Gynecol 188: 634-639.
45. Kimura SH, Ikawa M, Ito A, Okabe M, Nojima H, (2001) Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene 20: 3290-3300.
46. Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, et al. (2003) Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol Cancer Res 1: 195-206.
47. Garofalo M, Croce CM, (2010) microRNAs: Master Regulators as Potential Therapeutics in Cancer. Annu Rev Pharmacol Toxicol.
48. Wahid F, Shehzad A, Khan T, Kim YY, (2010) MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 1803: 1231-1243.
49. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899.
50. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
51. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S, (2008) The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 18: 89-102.